The federal court overseeing thousands of kidney damage lawsuits filed against the manufacturers of Nexium, Prilosec, PrevAcid, Dexilant, and Protonix has begun preparations for the multidistrict litigation’s first bellwether trials.
According to a Plaintiffs’ Letter filed with the U.S. District Court, District of New Jersey, on June 8th, the parties have reached an agreement on the litigation’s first such trial, proposing that it be convened in May 2020.
The matter was to be addressed by the Court yesterday, during the litigation’s June Status Conference. Other issues that were to be taken up at that time include:
There are currently more than 4,200 proton pump inhibitor lawsuits pending in the U.S. District Court, District of New Jersey, all of which put forth similar allegations regarding the potential for Nexium and similar heart burn drugs to damage the kidneys, resulting in kidney failure, chronic kidney disease, acute kidney injury, and acute interstitial nephritis.
Millions of people throughout the United States use prescription and over-the-counter proton pump inhibitors to treat GERD and other acid-related stomach disorders. While they are widely believed to be safe, a growing body of research suggests that long-term use may increase an individual’s risk for bone fractures, certain bacterial infections, heart attacks, dementia, vitamin B deficiency, and low magnesium.
In December 2014, the labels for prescription proton pump inhibitors were updated to note acute interstitial nephritis as a potential side effect. However, the prescribing information does not mention any other possible renal complications.
Since then, numerous studies have suggested that long-term proton pump inhibitor use may compromise kidney function: